However, when low CD45RA+/CD45RO+ and high CCL20+/CCR6+ ‘immunoscores’ were analyzed in combination, we observed 5 CIN II and 2 CIN III patients with this profile, similar to that described in the CIN I group. The gene discussed is CCR6; the disease is uterine cervix carcinoma in situ.